logo
Dennis Lo bets on blood to bare all, with tests that saved 10 million mums from the needle

Dennis Lo bets on blood to bare all, with tests that saved 10 million mums from the needle

Yahoo22-02-2025
In the first instalment of a series to mark the 10th anniversary of the Future Science Prize, Holly Chik and Shen Xinmei look at Professor Dennis Lo's groundbreaking discovery of fetal DNA in maternal plasma, which earned him the inaugural award in the Life Sciences category in 2016.
The blood tests of the future can reveal a lot more about a person's health, from neurodegenerative conditions to age-related diseases, said the Hong Kong clinical pathologist whose pioneering work in 1995 spared 10 million expecting mothers worldwide from the amniocentesis needle.
"In neurodegenerative diseases like Alzheimer's, I [can] use circular nucleic acids to diagnose those conditions", said Professor Dennis Lo Yuk-ming during an interview last month with the Post. "Ageing changes the formatting of DNA, so [one] can use epigenetics as a clock of the DNA."
Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.
Professor Dennis Lo Yuk-Ming in his laboratory at the Centre for Novstics at the Hong Kong Science and Technology Park on 21 June 2023. Photo: Yik Yeung-man
The T21 test, available for between HK$4,500 (US$578) and HK$8,000 at various hospitals and clinics in Hong Kong, has been rolled out to women in 90 countries since 2011.
For his work, Lo received the inaugural Future Science Prize for life science in 2016, and was named the Thomson Reuters Citation Laureate the same year, considered an index of the most promising Nobel Prize winners. Six years later, he received the Laskey-DeBakey Clinical Medical Research Award, a top US biomedical research prize.
The Chinese University of Hong Kong's president, Professor Dennis Lo Yuk-ming, with the painting that inspired his discovery of genetic markers in human blood, at his office in the Hong Kong Science & Technology Park on 7 January 2025. Photo: Jonathan Wong.
Inspired by a painting that depicted railway signals, Lo made more discoveries of what he called markers through the genetic material in the human blood, including circular nucleic acids, or molecules that carry genetic information in closed-loop structures.
The discovery widened the possible applications, including a blood test to identify areas of the brain that are contributing to neurological issues. That would save the person from undergoing an MRI scan, saving time and money, he said.
Blood tests in epigenetics, or the study of chemical reactions that influence the way genes work, can also be used to measure ageing in human organs, he said. "Is one or more of the organs ageing faster than others?" he said. "If that is the case, can we do something to slow that down?"
Extracting DNA from a woman's amniotic fluid for genome sequencing during the "CUHK Pioneers Whole Genome Sequencing for Prenatal Diagnosis in Hong Kong" at the Prince of Wales Hospital in Sha Tin on 17 September 2019. Photo: David Wong.
"Breakthroughs usually come up if you can see the hidden link between apparently unrelated subjects", Lo said in looking back at his career. "In my story, it was pregnancy, linked to transplant and to cancer."
As a medical student at The University of Oxford in the late 1980s, Lo aspired to develop a new technique to replace amniocentesis, an invasive and risky procedure of inserting a needle into the uterus to obtain fetal DNA.
He thought long and hard about the "possibility that the fetus might release cells into the mother's bloodstream, but that thinking at the time was not [in the] mainstream because we knew that the fetal blood circulation system is separate from the mother's", he said. "Theoretically, what I was proposing was not very feasible."
A blood test for health screenings during a health exhibition on common respiratory diseases organised by Chinese University of Hong Kong's Medical Society at Sunshine City in Ma On Shan on 5 October 2024. Photo: Edmond So
He persisted, launching his research after studying about polymerase chain reaction (PCR), a technique for amplify DNA molecules and making millions of their copies, from the geneticist John Bell, who later served as the Chair of Medicine at Oxford.
Lo sought out to find Y chromosomes, the male-determining gene, in a pregnant woman's blood. Still, the number of fetal cells that entered the maternal bloodstream was very small, not enough to be usable as a robust test.
After eight years of work, Lo returned to Hong Kong in 1997 in search of a change of direction. He decided to switch his focus to blood plasma, the light-yellowish liquid that carries the platelets, the red blood cells and white blood cells.
Blood plasma being prepared at a blood bank in Zhenjiang city in eastern China's Jiangsu province on August 2, 2014. Photo: Xinhua.
Even then, the conventional wisdom was that DNA did not float outside cells. As he gazed into a boiling pot of instant noodles one night, Lo had his eureka moment.
"I arrived at something really simple: take some plasma, boil it for five minutes and test a few drops of that boiled soup with PCR", he said, noting that DNA is robust enough to withstand heat. "Lo and behold, the signal occurred, much stronger than if you used the cells. In plasma, there are enzymes which might degrade the DNA. So if you heat that, you kill those enzymes, leaving the DNA behind."
After the T21 blood test came into clinical use, Lo shifted his search to male cells in women, and organ transplants came to mind.
Professor Dennis Lo Yuk-ming with a RNA microchip, used to detect RNA molecules located on chromosome 21, at the Postgraduate Education Centre of the Faculty of Medicine at the Prince of Wales Hospital in Sha Tin on 9 January, 2007. Photo: SCMP
His studies showed that Y chromosomes could be detected in the blood of women who received men's transplanted kidney or liver, a discovery that led to the development of tools for detecting transplant rejections.
"If the body rejects an organ, more cells are killed, [so] when the cells die, they release the DNA into the bloodstream", he said. "If you successfully treat that, the [detected DNA] level would come down."
Blood tests can also be used to detect cancer, because pregnancies and tumours are both "invasive" in essence to the host body.
"A baby growing inside a mother is a little bit invasive to the placenta, just like a cancer growing in a patient", he said.
While Down syndrome occurs because of an extra copy of the 21st chromosome pair, gene amplification is common in cancer cells, where certain genes that are advantageous to the growth of cancer produce more copies. These genes are detectable in a similar way to chromosome 21.
(Left to Right) Allen Chan Kwan-chee, Professor of Chemical Pathology at CU Medicine; Professor Dennis Lo Yuk-Ming, Director of the Li Ka Shing Institute of Health Sciences at Chinese University of Hong Kong (CUHK); and Dr. Jacky Lam Wai-kei, Assistant Dean (Research), Assistant Professor, Department of Chemical Pathology at CU Medicine, during a press conference on a CUHK study about the early detection of nasopharyngeal cancer on 11 July 2023. Photo: May Tse
Lo and his team developed a blood test for detecting cancers, starting with nasopharyngeal carcinoma, a type of cancer in the throat from the back of the nose to the back of the mouth, which is more prevalent in southern China than Western countries.
The future does not end there. The blood-brain barrier, the semi-permeable membrane between the blood and the interstitium of the brain, holds great potential for exploration.
Future blood tests could incorporate DNA reading into their current roles of evaluating organ function and helping diagnose diseases, Lo said.
"In the future, a blood test would also involve this type of technology", he said. "Apart from our usual liver function tests, they may also read out DNA signs."
"Blood plasma carries DNA released by different parts of a body. We can decipher the mixture back into their various sources", he said. "If there are injuries to organs, the representation from that part [of the body] would increase," making it possible to decipher the histories of strokes or heart attacks from blood, he said.
Asked about the global health impact he would like his research to have, Lo said "our goal is to maintain our health for as long as possible and to make it accessible to as many people as we can."
This article originally appeared in the South China Morning Post (SCMP), the most authoritative voice reporting on China and Asia for more than a century. For more SCMP stories, please explore the SCMP app or visit the SCMP's Facebook and Twitter pages. Copyright © 2025 South China Morning Post Publishers Ltd. All rights reserved.
Copyright (c) 2025. South China Morning Post Publishers Ltd. All rights reserved.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gates Foundation's new world-first contraceptive for African women: what it means for Africa
Gates Foundation's new world-first contraceptive for African women: what it means for Africa

Business Insider

time2 hours ago

  • Business Insider

Gates Foundation's new world-first contraceptive for African women: what it means for Africa

The Bill & Melinda Gates Foundation is set to launch a new long-acting contraceptive in Africa, beginning with Kenya later this year, as part of a US$2.5 billion commitment to accelerate research and expand services for the health of African women. The Bill & Melinda Gates Foundation is launching a new affordable long-term contraceptive in Africa, starting with Kenya. The contraceptives, including a hormonal IUD effective for up to eight years and a contraceptive patch, aim to address obstacles such as cost and accessibility. While receiving praise, concerns were raised about the ethical implications of externally funded family planning initiatives in Africa. This innovation by the Bill and Melinda Gates foundation follows research showing poor health outcomes for African women, particularly those in underserved communities, and limited R&D funding for women's health conditions beyond cancer. ' Today, women's health issues are still too often misunderstood, misdiagnosed, or ignored. Although women generally live longer than men, they spend 25% more of their lives in poor health. ' Ru-fong Joanne Cheng, Director, Women's Health Innovations, Gates Foundation noted. The new contraceptive: an affordable hormonal intrauterine device (IUD)—is designed to be effective for up to eight years, and will provide a discreet option for women in low-income households. ' A new hormonal IUD designed for affordability and a user-centered experience is being launched in Kenya, Nigeria, and possibly India, ' Dr Anita Zaidi, head of the Gender Equality Division at the Gates Foundation noted. The device is inserted into the uterus, where it releases progestin, a synthetic hormone that thickens cervical mucus to prevent sperm from reaching and fertilising an egg. Ru-fong described the revolutionary contraceptive patch, saying, 'I magine getting six months of contraceptive protection by pressing a small patch onto your skin. Discreet and self-administered.' She further explained that the patch is embedded with microneedles containing progestin, which delivers protection over several months. The foundation emphasized that the new programme will 'ensure that women and girls in low and middle-income countries can access the contraceptives and family planning information they want and thus exercise their right to decide whether to have children and, if so, when and how many.' Dr. Anita also noted that the programme builds on the foundation's 25-year work in maternal and child health, aimed at ending preventable deaths, eliminating deadly infectious diseases, and lifting millions out of poverty by 2045. 'Many women in these communities want to have control over their reproductive health but do not use existing contraceptive methods because of male interference, concerns about side effects, or lack of access to options that meet their specific needs. As a result, nearly half of all pregnancies worldwide—about 45%—are unplanned ' the Foundation said With the help of regional partners and government, the Gates foundation will expand access to the self-injectable contraceptive DMPA-SC to at least 35 countries, including Uganda, Senegal, Malawi, Nigeria, Zambia, and the Democratic Republic of Congo. Other funded innovations include rapid testing for sexually transmitted infections, AI-enabled ultrasound devices, and vaginal health therapies. Why Africa is the Focus According to the Foundation, Sub-Saharan Africa has some of the highest rates of unmet need for family planning globally, with barriers ranging from cost and distance to health facilities to cultural opposition. Many countries also face high rates of adolescent pregnancies, maternal mortality, and limited reproductive health infrastructure. By targeting Africa, the initiative seeks to provide longer-lasting, affordable options in regions where demand for family planning remains largely unmet. As Melinda French Gates emphasized, ' Contraceptives are one of the most powerful tools we have. It puts the power in the hands of young girls and women to plan their families, and quite honestly, to plan their futures.' Potential Implications However, some critics raise concerns that contraceptive programs in Africa may be perceived as externally imposed population control. This notion further suggests that the continent is being used as a testing ground for global health innovations, noting that similar large-scale rollouts are less visible in wealthier nations. Considering concerns from billionaires like Elon Musk and western pro-life activists about declining populations in their own countries, which highlight contrasting demographic priorities, critics argue that the new program not only focuses on population control but also risks taking away one of Africa's major advantages: its growing population.

Final trailer for Alien: Earth drops another xenomorph tease, but I'm far more interested in the horror show's other unsettling creatures
Final trailer for Alien: Earth drops another xenomorph tease, but I'm far more interested in the horror show's other unsettling creatures

Yahoo

time2 hours ago

  • Yahoo

Final trailer for Alien: Earth drops another xenomorph tease, but I'm far more interested in the horror show's other unsettling creatures

When you buy through links on our articles, Future and its syndication partners may earn a commission. The final trailer for FX's Alien: Earth has been released It'll premiere on Hulu and Disney+ in mid-August The sci-fi horror franchise's iconic Xenomorph won't be the show's most interesting monster There's less than a month to go (at the time of publication) until Alien: Earth crash-lands on our screens. So, what better way is there to celebrate than the release of one final, terror-fuelled trailer? With the sci-fi horror show set to launch on Hulu (US) and Disney+ (internationally) in mid-August, FX Networks has decided to release one more teaser to further whet our appetite for its release. And, if you thought the Alien franchise's iconic xenomorph would be the most frightening monster that'll show up, you'd better think again. Sure, the fan-favorite biological weapon will appear in the Alien franchise's first-ever TV show. That much has been made clear ever since Alien: Earth's underwhelming first teaser dropped in September 2024. It's the show's other skin-crawling creatures, though, that have piqued my interest since FX birthed another teaser for Alien: Earth in late April. Indeed, we caught glimpses of the other extraterrestrial beings that'll show up in the series in Alien: Earth's first proper trailer in June. Now, we have confirmation of not only how many we'll actually see, but the threat they'll pose to the human and android characters who populate the show. "This ship collected specimens – five new lifeforms – from distant planets," Babou Ceesay's Morrow can he heard saying in the latest round of footage. "[They're] monsters." You can say that again. From the carnivorous venus flytrap-like creature – D. Plumricarl – seen dangling from a ceiling (see the image above) to the eye-based lifeform – T. Ocellus – that's bonded to an unsuspecting sheep (see the image below), Sydney Chandler's Wendy, Morrow, and company won't want to mess around with these life-threatening species from other worlds. For those of you who missed it first time around, here's the story brief for Alien: Earth, courtesy of FX: "In the year 2120, the Earth is governed by five corporations: Prodigy, Weyland-Yutani, Lynch, Dynamic, and Threshold. "In this Corporate Era, cyborgs – humans with both biological and artificial parts – and synthetics – humanoid robots with artificial intelligence – exist alongside humans. But, the game is changed when the wunderkind Founder and CEO of Prodigy Corporation unlocks a new technological advancement: hybrids, humanoid robots infused with human consciousness." "The first hybrid prototype named 'Wendy' (Chandler) marks a new dawn in the race for immortality. After Weyland-Yutani's spaceship collides into Prodigy City, 'Wendy' and the other hybrids encounter mysterious life forms more terrifying than anyone could have ever imagined." Joining Chandler and Ceesay on the show's cast roster are Timothy Olyphant, Alex Lawther, Samuel Blenkin, Essie Davis, Kit Young, David Rysdahl, Lily Newmark, and Sandra Yi Sencindiver, among others. You can read more about the show's extensive cast, plot details, and its future in our ultimate guide to Alien: Earth. As we revealed in mid-May, Alien: Earth will be released on August 12. Well, in the US, plus other North American countries, and South America. In Europe, Africa, Asia, and Australia, it'll arrive on August 13. You might also like First trailer for Predator: Badlands drops two huge clues that it could be a new Alien Vs Predator movie in all but name See if you agree with our ranking of the best Alien movies Read our best Hulu movies guide to find out if any Alien movies appear on it Solve the daily Crossword

Gilead's Yeztugo sales 'ahead of expectations' following launch
Gilead's Yeztugo sales 'ahead of expectations' following launch

Yahoo

time8 hours ago

  • Yahoo

Gilead's Yeztugo sales 'ahead of expectations' following launch

After Gilead Sciences was given the green light for Yeztugo (lenacapavir) in the US and Europe, CCO Johanna Mercier said it is 'well ahead of expectations' in a Q2 investor call. The twice-yearly pre-exposure prophylaxis (PrEP) therapy has made headlines for its capacity to prevent 100% of HIV cases in a trial involving South African and Ugandan women – resulting in the jab's approval in June. While Gilead did not reveal how much the flagship drug has made for the company thus far, Mercier noted that unaided awareness on Yeztugo was 'at about 72%,' which is 'more than double that you'd see in industry at launch'. Looking forward, GlobalData, parent company of Pharmaceutical Technology, has forecasted that the star HIV drug will bring in just under $5bn in 2031, making it one of the company's most lucrative assets. However, some analysts had concerns about the drug's future uptake following the Supreme Court's ruling to allow Robert F. Kennedy Jr. (RFK Jr.) free rein over the US Preventive Services Task Force's (USPSTF) staffing and decision-making. Though the USPSTF currently recommends the use of Yeztugo as a preventive therapy for HIV, analysts feared that the division's restructure or complete overhaul could impact guidelines around the PrEP's usage, though Mercier believes that Gilead could 'work through it' by collaborating closely with its payers if this were to occur. The World Health Organisation (WHO) also recently announced new guidelines, which shift the agency's focus to preventive treatments, while prioritising the lowering of barriers to patient care for HIV management. Gilead has pledged to allow affordable Yeztugo in low-and middle-income countries after UNAIDS' executive director, Winnie Byanyima, called upon Gilead to allow for the immediate production of Yeztugo generics, as the drug's $40k US price tag could leave many in lower-income countries unable to afford treatment. HIV portfolio drives Gilead's overall growth On top of the early-stage success enjoyed by Yeztugo, Gilead has reported positive results for its HIV portfolio as a whole, with sales in this indication totalling $4.15bn this quarter. Blockbuster antiretroviral Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) also had 'one of its best quarters ever,' with sales jumping 9% to $3.5bn – constituting nearly half of the pharma's overall profits in the second quarter. Though the drug's patent is set to expire in October 2027, GlobalData's infectious disease analyst Anaelle Tannen noted that no HIV therapy is likely to be superior to Biktarvy in terms of commercial success. This is supported by GlobalData's forecast of a sales drop for Biktarvy's main competitor Dovato (dolutegravir and lamivudine), produced by ViiV Healthcare, which GlobalData forecasts will drop from $3.4bn in 2027 to $1.6bn in 2031, in part due to patents likely being made available in 2031. Though the HIV market is highly lucrative, with GlobalData predicting the HIV market will surpass $32bn across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan). There are more than 40 drugs now approved for use in the indication, meaning pharma companies will have to differentiate themselves substantially to get a slice of this crowded market. One way companies are trying to differentiate is through the development of an HIV vaccine. While none have yet shown great promise, with two trials by Scripps Research, IAVI and additional collaborators across the US and Africa showing proof of concept at Phase I. "Gilead's Yeztugo sales 'ahead of expectations' following launch" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store